Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 341

1.

Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza a virus hemagglutinin.

Tan GS, Lee PS, Hoffman RM, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P.

J Virol. 2014 Dec 1;88(23):13580-92. doi: 10.1128/JVI.02289-14. Epub 2014 Sep 10.

PMID:
25210195
[PubMed - in process]
2.

Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans.

Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F.

J Virol. 2014 Nov 15;88(22):13260-8. doi: 10.1128/JVI.02133-14. Epub 2014 Sep 10.

PMID:
25210189
[PubMed - in process]
3.

Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.

Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, Chang CY, Davis CW, McCausland M, Elbein R, Edupuganti S, Spearman P, Andrews SF, Wilson PC, García-Sastre A, Mulligan MJ, Mehta AK, Palese P, Ahmed R.

Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13133-8. doi: 10.1073/pnas.1414070111. Epub 2014 Aug 25.

PMID:
25157133
[PubMed - in process]
4.

Long-term survival of influenza virus infected club cells drives immunopathology.

Heaton NS, Langlois RA, Sachs D, Lim JK, Palese P, tenOever BR.

J Exp Med. 2014 Aug 25;211(9):1707-14. doi: 10.1084/jem.20140488. Epub 2014 Aug 18.

PMID:
25135297
[PubMed - indexed for MEDLINE]
5.

Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin.

Krammer F, Palese P, Steel J.

Curr Top Microbiol Immunol. 2015;386:301-21. doi: 10.1007/82_2014_408.

PMID:
25007847
[PubMed - in process]
6.

Peering into the crystal ball: influenza pandemics and vaccine efficacy.

Miller MS, Palese P.

Cell. 2014 Apr 10;157(2):294-9. doi: 10.1016/j.cell.2014.03.023.

PMID:
24725400
[PubMed - indexed for MEDLINE]
7.

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP.

Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095.

PMID:
24598590
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Divergent H7 immunogens offer protection from H7N9 virus challenge.

Krammer F, Albrecht RA, Tan GS, Margine I, Hai R, Schmolke M, Runstadler J, Andrews SF, Wilson PC, Cox RJ, Treanor JJ, García-Sastre A, Palese P.

J Virol. 2014 Apr;88(8):3976-85. doi: 10.1128/JVI.03095-13. Epub 2014 Jan 22.

PMID:
24453375
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

DiLillo DJ, Tan GS, Palese P, Ravetch JV.

Nat Med. 2014 Feb;20(2):143-51. doi: 10.1038/nm.3443. Epub 2014 Jan 12.

PMID:
24412922
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.

Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, Ryder AB, Miller MS, Rose JK, Palese P, García-Sastre A, Albrecht RA.

J Virol. 2014 Mar;88(6):3432-42. doi: 10.1128/JVI.03004-13. Epub 2014 Jan 8.

PMID:
24403585
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Universal influenza virus vaccines: need for clinical trials.

Krammer F, Palese P.

Nat Immunol. 2014 Jan;15(1):3-5. doi: 10.1038/ni.2761. No abstract available.

PMID:
24352315
[PubMed - indexed for MEDLINE]
12.

Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.

Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solórzano A, García-Sastre A, Palese P, Bouvier NM.

Nat Commun. 2013;4:2854. doi: 10.1038/ncomms3854.

PMID:
24326875
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge.

Krammer F, Margine I, Hai R, Flood A, Hirsh A, Tsvetnitsky V, Chen D, Palese P.

J Virol. 2014 Feb;88(4):2340-3. doi: 10.1128/JVI.03183-13. Epub 2013 Dec 4.

PMID:
24307585
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system.

Margine I, Palese P, Krammer F.

J Vis Exp. 2013 Nov 6;(81):e51112. doi: 10.3791/51112.

PMID:
24300384
[PubMed - indexed for MEDLINE]
15.

Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins.

Heaton NS, Sachs D, Chen CJ, Hai R, Palese P.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20248-53. doi: 10.1073/pnas.1320524110. Epub 2013 Nov 25.

PMID:
24277853
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies.

Goff PH, Eggink D, Seibert CW, Hai R, Martínez-Gil L, Krammer F, Palese P.

PLoS One. 2013 Nov 6;8(11):e79194. doi: 10.1371/journal.pone.0079194. eCollection 2013.

PMID:
24223176
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain.

Eggink D, Goff PH, Palese P.

J Virol. 2014 Jan;88(1):699-704. doi: 10.1128/JVI.02608-13. Epub 2013 Oct 23.

PMID:
24155380
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Krammer F, Palese P.

Curr Opin Virol. 2013 Oct;3(5):521-30. doi: 10.1016/j.coviro.2013.07.007. Epub 2013 Aug 24. Review.

PMID:
23978327
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, Palese P.

Sci Transl Med. 2013 Aug 14;5(198):198ra107. doi: 10.1126/scitranslmed.3006637.

PMID:
23946196
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.

Margine I, Krammer F, Hai R, Heaton NS, Tan GS, Andrews SA, Runstadler JA, Wilson PC, Albrecht RA, García-Sastre A, Palese P.

J Virol. 2013 Oct;87(19):10435-46. doi: 10.1128/JVI.01715-13. Epub 2013 Jul 31.

PMID:
23903831
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk